Tempus AI Achieves First GAAP Profit and Raises 2026 Revenue Guidance

Key Facts

1Tempus AI reported its first GAAP profit alongside accelerated growth in its data business segment.

2The company raised its 2026 revenue guidance to a range of $1.595B–$1.605B, representing a 25% year-over-year increase.

3FDA approval for xT CDx is expected to contribute approximately $400M in incremental revenue by 2028.

In a move reflecting the maturing business models of healthcare AI firms, Tempus AI reported its first profit under Generally Accepted Accounting Principles (GAAP). This milestone was primarily driven by accelerated growth within the company's data business segment, signaling a successful transition toward sustainable profitability for the growth-stage firm.

Following these results, the company raised its 2026 revenue guidance to a range of $1.595 billion to $1.605 billion, representing a 25% year-over-year increase. Furthermore, the FDA approval for xT CDx is projected to contribute approximately $400 million in incremental revenue by 2028, bolstered by high gross margins in the Data & Apps division reaching between 72% and 75%.

Regarding the broader economic environment, market data from August 12, 2026, showed U.S. annual inflation holding steady at 3.4%, providing a stable backdrop for growth stocks. While specific price levels for TEM are currently unavailable, investors are monitoring continued operating leverage in oncology and data services as primary catalysts for future valuation.

Sources:

seekingalpha.com